Search research articles
Contact Us
Filters
Showing results (191-200 of 229) with videos related to
Page
of 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease management
N Chiannilkulchai, P Pautier, C Genestie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
H Blons, J Abdelli, S Landman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
P Pautier, A Floquet, L Gladieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annales De Pathologie
|
November 28, 2006
[Recommendations for the management of gastro-intestinal stromal tumors]
A Le Cesne, B Landi, S Bonvalot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
E Bernichon, A Vallard, Q Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
A Le Cesne, J-Y Blay, D Cupissol, et al.
Gynecologic Oncology
|
April 8, 2022
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)
S Henno, C Jeanne, T De La Motte Rouge, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 229) with videos related to
Sort By:
Page
of 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease management
N Chiannilkulchai, P Pautier, C Genestie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
H Blons, J Abdelli, S Landman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
P Pautier, A Floquet, L Gladieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annales De Pathologie
|
November 28, 2006
[Recommendations for the management of gastro-intestinal stromal tumors]
A Le Cesne, B Landi, S Bonvalot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
E Bernichon, A Vallard, Q Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
A Le Cesne, J-Y Blay, D Cupissol, et al.
Gynecologic Oncology
|
April 8, 2022
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)
S Henno, C Jeanne, T De La Motte Rouge, et al.
Page
of 23